Importantly, alpelisib “off-label” activating PIK3CA mutations (those not detected by therascreen®PIK3CA RGQ PCR Kit in SOLAR-1 trial) were seen in 388 (7.9%) of all breast tumors (12). The gene discussed is PIK3CA; the disease is breast neoplasm.